Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator - Wikidata - wikimedia - TriplyDB

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

http://www.wikidata.org/entity/Q28183674

about

Probing a protein-protein interaction by in vitro evolution The future of biologic agents in the treatment of Sjögren's syndrome The current status of targeting BAFF/BLyS for autoimmune diseases B-cell survival factors in autoimmune rheumatic disorders Belimumab in systemic lupus erythematosus: a perspective review Cellular targeting in autoimmunity Drugs derived from phage display: from candidate identification to clinical practice A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus A therapeutic role for BLyS antagonists BAFF and rheumatic autoimmune disorders: implications for disease management and therapy A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study.Airway epithelial cells produce B cell-activating factor of TNF family by an IFN-beta-dependent mechanism.Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Beyond natural antibodies: the power of in vitro display technologies.Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.Detection of biomarkers using recombinant antibodies coupled to nanostructured platforms Efficacy and safety data of belimumab in patients with systemic lupus erythematosus.Tailored amino acid diversity for the evolution of antibody affinity MiR-30a-3p negatively regulates BAFF synthesis in systemic sclerosis and rheumatoid arthritis fibroblasts.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.Generation and analysis of the improved human HAL9/10 antibody phage display libraries.Advances in phage display technology for drug discovery.Cytokine disturbances in systemic lupus erythematosus.BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus The discovery and development of belimumab: the anti-BLyS-lupus connection BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders.Prospects for B-cell-targeted therapy in autoimmune disease.Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus Challenges in bringing the bench to bedside in drug development for SLE.Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.Applications of ribosome display to antibody drug discovery.

P2860

Q24546265-BC95F1A4-078A-41BE-9A58-C96D3F353530 Q24681044-CAF91484-DD6C-4CF4-90E7-77C889FD7952 Q24796930-95F63271-CA43-41F9-8976-1C19B7B185F2 Q26796484-CF554D4F-DA10-4F92-B778-2DEE0BEE9DE6 Q26796486-C72E47B1-B4A5-4D32-B8CC-81C80F5F34EA Q26824580-6FC8F65B-9B5D-49E0-AFAB-C00D29E315F8 Q27007101-20081323-5B27-4AA1-9F6F-48DF57E10F03 Q28254310-32BAF62B-2FED-41F3-99F6-DA7E8B030244 Q28269809-96D86383-FD7C-4DDD-839E-E99AB6D9E164 Q28292058-6FF730E1-BEB0-4769-A145-632DDD5BB15A Q28293722-44AAE645-04E4-4B16-8319-FFFAFE7A3795 Q30490276-73932FA9-6862-4148-AA61-025A71C3A614 Q33584291-D734F41D-0A34-4696-96A5-5399DF8DB310 Q33586280-C489EA52-870B-4A2B-BC80-1B785F2F1C3E Q33601679-666408D2-1F1A-4035-8C0B-EFC69C12B1F8 Q33688370-DAF74235-477B-4EAC-BA0B-E35708342596 Q33695128-B165D98C-BE55-466A-869B-9E89F23D7462 Q33698040-9A9E55B1-4C56-4C04-8879-693C7949DEEE Q33803763-2FBCEB27-BB67-43FA-A40F-55F35D953439 Q33841864-8A955BE9-BF57-4C0B-8360-8C3D6504D8FB Q33960050-BE846A00-2131-4C33-A90E-D6C431795C48 Q34245983-07516358-43EB-4559-92CC-4FCB593FA782 Q34352221-82465E39-A88F-4204-BA2C-F3109B7B0A96 Q34369628-637A2EEA-BEBB-4B9D-AE0C-AF3219FB0817 Q34394742-81D91C43-FE84-4EE8-B510-082F19F49909 Q34434727-5A350CD1-0BC3-4AD4-A1FA-952836BF0A3F Q34960458-608A33CE-E9CB-4D6A-928A-9ED3DDFAF3AF Q35008162-C7BEC168-B19F-43F7-B2CC-688342396613 Q35608279-AC6B8E31-3ADA-43E5-A96B-CE445E581E2B Q35614190-85937B32-C9B6-47AD-B33D-1A899A5AD20A Q35617573-BEDFB380-C943-4EFA-BDA1-5B3C22777788 Q35686772-365B990D-EE18-401A-8FF4-D7C02560F509 Q35691272-53894907-E07D-4AE9-8015-3850A7D7F6D3 Q35732635-A9FEFBEF-2C3B-450E-994D-5015447F25F4 Q35782879-ADF82103-6310-4F69-9C1D-75AF40A520EC Q35930307-F0823D56-9037-4B4B-8DF4-4303357564DD Q35954719-57A1B9D2-B154-4E34-9E1F-6552C21420B8 Q35968394-1BED23CF-68E2-46A0-89D0-4D0535F677CE Q35986113-8665B1D9-E29C-4845-BC78-EBC9A62DB75A Q36040839-3413B2A5-80BB-43CD-915C-376AB3F790AF

P2860

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

http://www.wikidata.org/entity/Q28183674

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Generation and characterizatio ...... ies of B lymphocyte stimulator

@ast

Generation and characterizatio ...... ies of B lymphocyte stimulator

@en

Generation and characterizatio ...... ies of B lymphocyte stimulator

@nl

type

label

Generation and characterizatio ...... ies of B lymphocyte stimulator

@ast

Generation and characterizatio ...... ies of B lymphocyte stimulator

@en

Generation and characterizatio ...... ies of B lymphocyte stimulator

@nl

prefLabel

Generation and characterizatio ...... ies of B lymphocyte stimulator

@ast

Generation and characterizatio ...... ies of B lymphocyte stimulator

@en

Generation and characterizatio ...... ies of B lymphocyte stimulator

@nl

P1433

Q28183674-4BBF0184-41B6-4840-ACB7-9435B4F7813A

P1476

Q28183674-BE3AF487-B335-46F4-9C6D-39651A4BD540

P2093

Q28183674-01FC7F98-6BA8-4B56-8546-2AF41751801E

Q28183674-14FF0454-EB7D-4854-8106-C7998872EA19

Q28183674-1C0896C0-4422-4CE3-89A3-BFA6F7CDBE1C

Q28183674-1F294DB1-402A-4A43-9AAE-5BD2D462ADEB

Q28183674-291CACB5-D0BA-4F08-B801-F1D9C1E863A5

Q28183674-38FC9D79-1CBE-4341-A473-68B4FEA2C844

Q28183674-3D6B37A4-E62C-4A5C-92E3-0E9AE14AE768

Q28183674-4DCA121B-E757-41FA-81DC-88420A2958D5

Q28183674-4EDB33AD-6ECA-4E01-9D95-1C05985C93D9

Q28183674-644A22DD-4CAC-47E0-9F55-D9B5D83D5E35

P304

Q28183674-C9307C27-6496-407F-836E-1FBDC0AA92F3

P31

Q28183674-E5D25863-490B-4390-A5B8-F930C118157A

P3181

Q28183674-A21FADB3-ADD5-4848-9193-F894F55EF49D

P356

Q28183674-0B65FB9B-988A-41D8-8DF7-6CC3056E2B53

P407

Q28183674-D1E71349-00BC-4B1F-A3E0-567B9B148452

P433

Q28183674-159FFFE8-A5EA-4A46-A4C7-2F44A68CB92F

P478

Q28183674-22ABBE32-1D51-4098-A70D-0F8B71EA2135

P577

Q28183674-7107C877-D5E5-4139-B4A6-BCF3D563503D

P5875

Q28183674-880126A4-41CE-410F-A2F6-2F5A0FE0EC31

P698

Q28183674-97821ACA-0CD7-4E3F-B158-CB15A5BA20A0

P921

Q28183674-16C44C63-D6D5-4D14-AD59-7972DD17C715

Q28183674-DE7F782E-BCA3-4B0B-8A3E-F20A9633E0EB

P3181

P356

P1433

Arthritis & Rheumatology

P1476

Generation and characterizatio ...... ies of B lymphocyte stimulator

@en

P2093

Bonnie Sturm

http://www.w3.org/2001/XMLSchema#string

Bryan M Edwards

http://www.w3.org/2001/XMLSchema#string

Carol Poortman

http://www.w3.org/2001/XMLSchema#string

Claire L Dobson

http://www.w3.org/2001/XMLSchema#string

David M Hilbert

http://www.w3.org/2001/XMLSchema#string

Donara Abramian

http://www.w3.org/2001/XMLSchema#string

Elizabeth Williams

http://www.w3.org/2001/XMLSchema#string

Gil H Choi

http://www.w3.org/2001/XMLSchema#string

Kevin P Baker

http://www.w3.org/2001/XMLSchema#string

Les Sekut

http://www.w3.org/2001/XMLSchema#string

P304

3253-65

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3346937

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/ART.11299

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9013157

http://www.w3.org/2001/XMLSchema#string

P698

14613291

http://www.w3.org/2001/XMLSchema#string

P921